Search

Search Constraints

You searched for: Author/Creator Styren, Scot

Search Results

1. Alzheimer's disease assessment scale‐cognitive 11‐item progression model in mild‐to‐moderate Alzheimer's disease trials of bapineuzumab. Issue 3 (5th October 2015)

2. Alzheimer's disease progression model using disability assessment for dementia scores from bapineuzumab trials. Issue 2 (21st July 2015)

3. IC‐P‐015: Evaluation of the pons as a reference region for amyloid PET in Alzheimer's disease clinical trials. (1st July 2013)

4. Long-term safety and tolerability of bapineuzumab in patients with Alzheimer's disease in two phase 3 extension studies. Issue 1 (December 2016)

5. Multiple‐dose ponezumab for mild‐to‐moderate Alzheimer's disease: Safety and efficacy. Issue 3 (10th May 2017)

6. O1–06–02: Effect of bapineuzumab on CSF p‐tau and t‐tau in mild‐to‐moderate Alzheimer's disease: Results from two phase III trials in APOE‐ε4 carriers and noncarriers. (1st July 2013)

7. P1‐145: A PROSPECTIVE, SYSTEMATIC LITERATURE REVIEW AND META‐ANALYSES TO EVALUATE CEREBROSPINAL FLUID (CSF) PHOSPHORYLATED TAU (P‐TAU) AND TOTAL TAU (T‐TAU) AS BIOMARKERS OF ALZHEIMER'S DISEASE PROGRESSION. (1st July 2014)

8. P1‐146: A PROSPECTIVE, SYSTEMATIC LITERATURE REVIEW AND META‐ANALYSES TO EVALUATE BRAIN AMYLOID BY POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AS A BIOMARKER OF ALZHEIMER'S DISEASE (AD) PROGRESSION. (1st July 2014)

9. P1‐147: A PROSPECTIVE, SYSTEMATIC LITERATURE REVIEW AND META‐ANALYSES TO EVALUATE GLOBAL AND REGIONAL BRAIN VOLUMES BY STRUCTURAL MRI AS BIOMARKERS OF ALZHEIMER'S DISEASE (AD) PROGRESSION. (1st July 2014)

10. P1–346: Disease progression modeling of bapineuzumab utilizing Alzheimer's Disability Assessment for Dementia scores. (1st July 2013)